SCHEMBL30765756

SCHEMBL30765756

CCOC(=O)Cn1c(-c2ccccc2C)ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41
GABRE P78334 1/20 0.41
GABRA6 Q16445 1/20 0.41
GABRG1 Q8N1C3 1/20 0.41
GABRG3 Q99928 1/20 0.41
GABRQ Q9UN88 1/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
KDM4E B2RXH2 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558409 0.90 POLB (0.36) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765525 0.85 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19KDM4ERXFP1
SCHEMBL30765977 0.83 GAA (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30766151 0.82 ELANE (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765969 0.82 GAA (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765879 0.81 GAA (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765991 0.81 ELANE (0.42) CYP1A2CYP2C9CYP2C19KDM4ELMNA
SCHEMBL31558435 0.81 ELANE (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765556 0.81 GAA (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30765510 0.80 L3MBTL1 (0.41) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed